Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azeliragon Combined With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
NCT05635734Phase 2Completed
- Sponsor
- Cantex Pharmaceuticals, Inc.
- Start
- Sep 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azeliragon in glioblastoma (GBM), sponsored by Cantex Pharmaceuticals, Inc. Primary endpoint: Recommended phase 2/3 dose at 28 days. Started Sep 2023; status: completed.
02
Drugs
azeliragon
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05635734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635734.